Client Story
How PHM guided Matthew to groundbreaking therapies that addressed his advanced lung cancer.
Matthew, a 56-year-old executive and lifelong baseball fan, faced a challenging diagnosis of stage 4 lung cancer. Initially treated with radiation and targeted therapy for a specific mutation, his cancer became resistant to treatment.
Seeking new options, Matthew reached out to Private Health Management to obtain expert advice and explore healthcare options.
PHM utilized an advanced blood-based molecular test to analyze Matthew’s evolving cancer profile, identifying new mutations that contribute to treatment resistance. This crucial discovery enabled the development of a more precise strategy to combat his disease.
With these insights, PHM’s Personal Care Team facilitated Matthew’s enrollment in two consecutive clinical trials testing next-generation targeted therapies. These drugs, which have since received FDA approval, represent a new standard in lung cancer care. During the first trial, Matthew’s condition remained stable for over eight months, and in the second trial, he experienced an additional nine months of stability.
Matthew lived with stage 4 lung cancer for nearly five years, far exceeding typical expectations for his diagnosis. His case underscores PHM’s proficiency in utilizing groundbreaking diagnostics and clinical trials to provide life-prolonging treatment, offering hope and innovation for individuals with complex health issues.
Download our Cancer Survivability whitepaper for new insights and strategies into improving patient care and outcomes.
Discover our Why Wall
